Clinical trials
Immunoglobulin G4-Related Disease trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2012 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 8 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 14 |
| Unknown status | 13 |
| Not yet recruiting | 7 |
| Active, not recruiting | 3 |
| Completed | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peking Union Medical College Hospital | 14 |
| Chinese PLA General Hospital | 3 |
| Tongji Hospital | 3 |
| Wen Zhang | 3 |
| Amgen | 2 |
| Changhai Hospital | 2 |
| Peking University People's Hospital | 2 |
| Acepodia Biotech, Inc. | 1 |
| Beijing GoBroad Hospital | 1 |
| Changzhou No.2 People's Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Immunoglobulin G4-Related Disease | 40 |
| Autoimmune Diseases | 7 |
| Recurrence | 7 |
| Lupus Erythematosus, Systemic | 6 |
| Scleroderma, Systemic | 6 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 5 |
| Myositis | 5 |
| Lupus Nephritis | 4 |
| Antiphospholipid Syndrome | 2 |
| Arthritis, Rheumatoid | 2 |
Trials
Showing 51 to 40 of 40. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.